Navigation Links
Kiadis Pharma Receives IND Approval From FDA to Start Pivotal Clinical Trial With ATIR(TM) in the United States
Date:7/8/2010

AMSTERDAM, July 8 /PRNewswire/ -- Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States.  Kiadis Pharma is currently enrolling patients in a multinational, pivotal clinical study at hospitals in Europe and Canada.  With the approval of the IND, US hospitals will also participate in this study.

ATIR™ is designed for blood cancer patients in need of allogeneic bone marrow transplantation, who do not have a matched donor available.  ATIR™ allows a mismatched family member to act as donor, and is being developed to reduce Transplant Related Mortality without inducing Graft versus Host Disease (GvHD).

"We are very encouraged by this IND approval received from the FDA. We look forward to starting treatment of US patients in our ongoing multinational, pivotal clinical study, in which patients in Europe and Canada are already being treated," commented Manja Bouman, CEO of Kiadis Pharma.

ATIR™ has shown excellent clinical results in a phase I/II study in patients who received a haploidentical mismatched bone marrow transplantation from a family member donor.  The two year follow up data showed no Transplant Related Mortality (TRM) and overall survival of 70% in a group of high risk leukemia patients who received an efficacious dose of ATIR™.  These results compare favorably to outcomes of bone marrow transplantations from a ful
'/>"/>

SOURCE Kiadis Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
2. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
3. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
4. Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Cryoport, Inc. ... "Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, announced today that ... common stock and warrants (the "Units") under a registered ...
(Date:7/29/2015)... Colo., July 29, 2015 Heska Corporation ... a provider of advanced veterinary diagnostic and other specialty ... quarter ended June 30, 2015. Second Quarter ... Operations was up nearly 100% to $1.829 million, from $917 ... to $10.1 million, from $7.8 million. , Core Companion ...
(Date:7/29/2015)... , July 27, 2015 Research and ... of the "Global Neurostimulation Devices Market 2015" ... analysts forecast the global neurostimulation devices market to ... period 2014-2019. The report, Global Neurostimulation ... an in-depth market analysis with inputs from industry ...
Breaking Medicine Technology:Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Heska Reports Financial Results for the Second Quarter of 2015 2Heska Reports Financial Results for the Second Quarter of 2015 3Heska Reports Financial Results for the Second Quarter of 2015 4Heska Reports Financial Results for the Second Quarter of 2015 5Heska Reports Financial Results for the Second Quarter of 2015 6Heska Reports Financial Results for the Second Quarter of 2015 7Heska Reports Financial Results for the Second Quarter of 2015 8Global Neurostimulation Devices Market 2015-2019 2
... NEW YORK, Aug. 14 Immtech Pharmaceuticals,Inc. (Amex: ... paper published in Nucleic,Acids Research by a group ... ability of furamidine to inhibit a key enzyme ... Furamidine is the active metabolite (DB75),of Immtech,s proprietary, ...
... Scheduled Start of Phase 3 Clinical Trial, BELTSVILLE, ... has reported a second quarter 2007 loss from continuing,operations ... to a loss from,continuing operations of $699,000, or 5 ... from discontinued operations in the second quarter,of 2007 was ...
Cached Medicine Technology:Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3Spherix Reports Second Quarter Earnings 2
(Date:7/29/2015)... ... July 29, 2015 , ... The federal government ... drinking and substance abuse is having on lost productivity, workplace accidents and injuries, ... billions per year. [1] Will Wesch, Director of Admissions for Novus Medical ...
(Date:7/29/2015)... ... July 29, 2015 , ... Today the nonprofit Alliance ... through Vaccination in Older Adults, that provides a comprehensive overview of the factors ... and health care experts can improve patient compliance. , Although influenza, pneumococcal, tetanus, ...
(Date:7/29/2015)... ... ... Potomac Pilates, an elite Washington, D.C. metro area-based Pilates studio, is excited ... Potomac Pilates. On Thursday, July 30, Potomac Pilates will unveil its new name, ... will continue to offer the same classes and personal experiences their clients know and ...
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... ... comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive ... new targets and MOAs to produce first-in-class and best-in-class products. Complete report on ...
(Date:7/29/2015)... ... ... The healthcare analytics market is categorized on the basis ... the rising pressure to curb healthcare costs, big data in healthcare, technological advancements, ... driving market growth. Check 149 data tables & 57 figures spread through 200 ...
Breaking Medicine News(10 mins):Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 2Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 3Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5
... on the Impact of ... Technology in Healthcare, PLANO, ... - Perot Systems Chief Medical Officer & Executive Vice President ... Director for Microsoft, Perot Systems continues its series of podcasts ...
... states , , THURSDAY, March 13 (HealthDay News) -- An ... cell carcinoma appears to increase if she lives in areas ... a new study found. , The risk of developing another ... only moderately affected by living in areas with high UV ...
... Project Concern,International (PCI) recently received a US$1 million ... will enable PCI and its local,partner, ADRA/Tanzania, to ... in the water-stressed country of Tanzania., Less ... district have,access to clean water, a critical problem ...
... (IOF) has welcomed the recently published paper European ... in postmenopausal women(1) from the European Society for ... (ESCEO). , This paper constitutes a roadmap for ... tool based on the WHO technical report, Assessment ...
... Primary Children,s Medical Center of,Salt Lake City, Utah, ... a RIVA,System (Robotic IV Automation) - a self-contained ... Intelligent Hospital Systems (IH Systems). Owned,and operated by ... with complex illness and injury from across the,western ...
... Key Patient Resource on Restorative Options, HARRISBURG, ... is recommending that PDA member dentists use a ... when discussing,restorative options with patients., "The Pennsylvania ... latest information on oral health issues," said Dr. ...
Cached Medicine News:Health News:Healthcare Tech and the World: Personalized Technology to Benefit Healthcare Consumers in the Future 2Health News:Healthcare Tech and the World: Personalized Technology to Benefit Healthcare Consumers in the Future 3Health News:Women's Risk for a Certain Skin Cancer Varies by Geography 2Health News:Women's Risk for a Certain Skin Cancer Varies by Geography 3Health News:Project Concern International Receives a US$1 Million Grant From the Starbucks Foundation's Ethos Water Fund to Provide Safe Water and Sanitation Services in Tanzania 2Health News:IOF recognizes ESCEO European guidance for osteoporosis diagnosis and management 2Health News:RIVA's Cutting Edge Technology To Help Intermountain Healthcare Enhance Medication Delivery Safety 2Health News:Pennsylvania Dental Association Urges Members to Use New ADA Educational Material 2
... Hemoglobin Testing System: The D-10 Hemoglobin ... small package. It provides a fully automated ... testing into a single platform. Programs for ... touch screen away and can be easily ...
... The ADVIA 120 Hematology System gets ... right the first time, with a ... systems. Results are more accurate, physicians ... more effective. The ADVIA 120 Hematology ...
... with the rapid, reliable test results that ... therapeutic monitoring. With the power of ... the XE-2100 offers a complete CBC with ... of NRBC, HPC and IG. Fully ...
... HmX offers three-dimensional VCS ... specificity and efficiency in ... reticulocyte analysis. With its ... dependability, HmX is an ...
Medicine Products: